Cargando…

The EHA Research Roadmap: Malignant Myeloid Diseases

Detalles Bibliográficos
Autores principales:	Döhner, Hartmut, Malcovati, Luca, Ossenkoppele, Gert J., Hochhaus, Andreas, Maria Vannucchi, Alessandro, Bullinger, Lars, Cervantes, Francisco, Craddock, Charles, de Witte, Theo, Döhner, Konstanze, Dombret, Hervé, Fenaux, Pierre, Geissler, Jan, Germing, Ulrich, Guilhot, Francois, Harrison, Claire, Hellström-Lindberg, Eva, Passamonti, Francesco, Sierra, Jorge, Skoda, Radek, Wierzbowska, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389885/ https://www.ncbi.nlm.nih.gov/pubmed/34476345 http://dx.doi.org/10.1097/HS9.0000000000000635

Ejemplares similares

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
por: Macintyre, Elizabeth, et al.
Publicado: (2020)

The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group
por: Gurnari, Carmelo, et al.
Publicado: (2022)

The EHA Research Roadmap: Anemias
por: Iolascon, Achille, et al.
Publicado: (2021)

The EHA Research Roadmap: Platelet Disorders
por: Balduini, Carlo, et al.
Publicado: (2021)

The EHA Research Roadmap: Normal Hematopoiesis
por: Jaffredo, Thierry, et al.
Publicado: (2021)

The EHA Research Roadmap: Infections in Hematology
por: Cordonnier, Catherine, et al.
Publicado: (2021)

The EHA Research Roadmap: Transfusion Medicine
por: Stanworth, Simon J., et al.
Publicado: (2022)

EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update
por: Iolascon, Achille, et al.
Publicado: (2019)

Correction Notice: The EHA Research Roadmap: Anemias
Publicado: (2021)

The EHA Research Roadmap: Malignant Lymphoid Diseases
por: Dreyling, Martin, et al.
Publicado: (2022)

The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders
por: Eichinger, Sabine, et al.
Publicado: (2021)

The EHA Research Roadmap: Hematopoietic Stem Cells and Allotransplantation
por: Fibbe, Willem, et al.
Publicado: (2022)

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2021)

The EHA Research Roadmap: Hematopoietic Stem Cell Gene Therapy
por: Naldini, Luigi, et al.
Publicado: (2022)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
por: Lueck, Sonja C., et al.
Publicado: (2016)

SEURAT: Visual analytics for the integrated analysis of microarray data
por: Gribov, Alexander, et al.
Publicado: (2010)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
por: Zhai, Yanan, et al.
Publicado: (2022)

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

S136: ANALYSIS OF FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY
por: Guarnera, Luca, et al.
Publicado: (2023)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
por: Kelly, Katherine, et al.
Publicado: (2023)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Telemedicine Networks of EHAS Foundation in Latin America
por: Prieto-Egido, Ignacio, et al.
Publicado: (2014)

EHA2021 Virtual Congress Abstract Book
Publicado: (2021)

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Defining disease modification in myelofibrosis in the era of targeted therapy
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice
por: Gentner, Eva, et al.
Publicado: (2016)

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
por: Buske, C., et al.
Publicado: (2022)

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair
por: Herzig, Julia K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_euhq9avi2u4dsfqh60rj34mbrg